Located in the Yanqi Economic Development Zone in Huairou District, Beijing, Beijing Honglin Pharmaceutical Co., Ltd. is GoeGoe Honglin Pharm.'s first R&D and manufacturing base established in China. With a registered capital of USD 15.8 million, it is a wholly U.S.-owned enterprise certified as a National High-Tech Enterprise. The company has extensive pharmaceutical manufacturing capabilities and receives technical support from a U.S.-based expert management team.

Located in Zhenjiang New District, Jiangsu Province, GoeGoe Honglin Biopharmaceutical (Jiangsu) Co., Ltd. represents a further expansion of GoeGoe Honglin Pharm.'s manufacturing footprint following the establishment of Beijing Honglin Pharmaceutical Co., Ltd. With a registered capital of USD 41 million and a site covering approximately 80,000 square meters, the facility integrates automated production lines, imported core process equipment, and advanced information and environmental control systems. Phase I has been completed and is now operational, while Phase II is currently under construction. Upon completion of the planned expansion, the annual capacity for sustained- and controlled-release formulations is expected to reach 4.5 billion tablets and capsules, supporting efficient and stable commercial-scale manufacturing.